Protara Therapeutics (TARA) Other Non-Current Liabilities (2015 - 2016)
Protara Therapeutics (TARA) recorded quarterly Other Non-Current Liabilities of $98000.0 in Q3 2016, down 59.34% quarter-over-quarter from $241000.0 in Q2 2016, and up 16.67% on a YoY basis from $84000.0 in Q4 2015.
Protara Therapeutics (TARA) Other Non-Current Liabilities (2015 - 2016) Analysis & Trends
Protara Therapeutics' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $98000.0 for Q3 2016.
- In Q3 2016, Other Non-Current Liabilities rose 16.67% year-over-year to $98000.0; the TTM figure through Sep 2016 stood at $98000.0 (up 16.67% YoY), while the FY2015 annual figure was $537000.0, changed N/A from the prior year.
- Other Non-Current Liabilities was $98000.0 for Q3 2016 at Protara Therapeutics, down from $241000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $537000.0 in Q4 2015 to a low of $51000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Protara Therapeutics | 216.35 Mn | 216.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 98,000.00 |
| Jun 30, 2016 | 241,000.00 |
| Mar 31, 2016 | 319,000.00 |
| Dec 31, 2015 | 537,000.00 |
| Sep 30, 2015 | 84,000.00 |
| Jun 30, 2015 | 51,000.00 |